Role of 5-HT1A receptors in fluoxetine-induced lordosis inhibition

Hormones and Behavior

Volumn 58, Issue 2, 2010, Pages 290-296

  Guptarak, Jutatip ^a   Sarkar, Jhimly ^a   Hiegel, Cindy ^a   Uphouse, Lynda ^a  

^a TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Antidepressant; Hormonal priming; Lordosis; Ovariectomized rat; Progesterone; Serotonin; Sexual dysfunction; SSRIs

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PROGESTERONE; SEROTONIN 1A RECEPTOR; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1 ANTAGONIST; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; LORDOSIS QUOTIENT; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; TOXICITY TESTING; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; FISCHER 344 RAT; METABOLISM; OVARIECTOMY; PHYSIOLOGY; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TIME;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOXETINE; MODELS, ANIMAL; OVARIECTOMY; PIPERAZINES; PROGESTERONE; PYRIDINES; RATS; RATS, INBRED F344; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SEXUAL BEHAVIOR, ANIMAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TIME FACTORS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT1 RECEPTOR ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS;

EID: 77953362322     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2010.03.003     Document Type: Article

References (72)

1. Ago Y., Koyama Y., Baba A., Matsuda T. Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex. Neuropharmacology 2003, 45:1050-1056.
2. Auerbach S.B., Minzenberg M.J., Wilkinson L.O. Extracellular serotonin and 5-hydroxyindoleacetic acid in hypothalamus of the unanesthetized rat measured by in vivo dialysis coupled to high-performance liquid chromatography with electrochemical detection: dialysate serotonin reflects neuronal release. Brain Res. 1989, 499:281-290.
3. Barbaccia M.L. Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs. Crit. Rev. Neurobiol. 2004, 16:67-74.
4. Benmansour S., Piotrowski J.P., Altamirano A.V., Frazer A. Impact of ovarian hormones on the modulation of the serotonin transporter by fluvoxamine. Neuropsychopharmacology 2009, 34:555-564.
5. Blaustein J.D. Neuroendocrine regulation of feminine sexual behavior: lessons from rodent models and thoughts about humans. Annu. Rev. Psychol. 2008, 59:93-118.
6. Castro E., Diaz A., Rodriguez-Gaztelumendi A., Del Olmo E., Pazos A. WAY100635 prevents the changes induced by fluoxetine upon the 5-HT1A receptor functionality. Neuropharmacology 2008, 55:1391-1396.
7. Clayton A., Keller A., McGarvey E.L. Burden of phase-specific sexual dysfunction with SSRIs. J. Affect. Disord. 2006, 91:27-32.
8. Cliffe I.A. A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands. Nucl. Med. Biol. 2000, 27:441-447.
9. Crane J.W., Shimizu K., Carrasco G.A., Garcia F., Jia C., Sullivan N.R., D'Souza D.N., Zhang Y., Van de Kar L.D., Muma N.A., Battaglia G. 5-HT1A receptors mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated kinase (MAP kinase) in vivo in rat hypothalamus: time dependence and regional differences. Brain Res. 2007, 1183:51-59.
10. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
11. Daws L.C., Gould G.G., Teicher S.D., Gerhardt G.A., Frazer A. 5-HT(1B) receptor-mediated regulation of serotonin clearance in rat hippocampus in vivo. J. Neurochem. 2000, 75:2113-2122.
12. Dawson L.A., Nguyen H.Q. The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. Neuropharmacology 2000, 39:1044-1052.
13. Erskine M.S. Solicitation behavior in the estrous female rat: a review. Horm. Behav. 1989, 23:473-502.
14. Farmer C.J., Isakson T.R., Coy D.J., Renner K.J. In vivo evidence for progesterone dependent decreases in serotonin release in the hypothalamus and midbrain central grey: relation to the induction of lordosis. Brain Res. 1996, 711:84-92.
15. Frankfurt M., McKittrick C.R., Mendelson S.D., McEwen B.S. Effect of 5, 7-dihydroxytryptamine, ovariectomy and gonadal steroids on serotonin receptor binding in rat brain. Neuroendocrinology 1994, 59:245-250.
16. Frye C.A., Rhodes M.E. Infusions of 5alpha-pregnan-3alpha-ol-20-one (3alpha, 5alpha-THP) to the ventral tegmental area, but not the substantia nigra, enhance exploratory, anti-anxiety, social and sexual behaviours and concomitantly increase 3alpha, 5alpha-THP concentrations in the hippocampus, diencephalon and cortex of ovariectomised oestrogen-primed rats. J. Neuroendocrinol. 2006, 18:960-975.
17. Frye C.A., Bayon L.E., Pursnani N.K., Purdy R.H. The neurosteroids, progesterone and 3alpha, 5alpha-THP, enhance sexual motivation, receptivity, and proceptivity in female rats. Brain Res. 1998, 808:72-83.
18. Frye C.A., Petralia S.M., Rhodes M.E., Stein B. Fluoxetine may influence lordosis of rats through effects on midbrain 3 alpha, 5 alpha-THP concentrations. Ann. N. Y. Acad. Sci. 2003, 1007:37-41.
19. Frye C.A., Rhodes M.E., Petralia S.M., Walf A.A., Sumida K., Edinger K.L. 3alpha-Hydroxy-5alpha-pregnan-20-one in the midbrain ventral tegmental area mediates social, sexual, and affective behaviors. Neuroscience 2006, 138:1007-1014.
20. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., Khan Z.M. Antidepressant-induced sexual dysfunction. Ann. Pharmacother. 2002, 36:1577-1589.
21. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13512-13517.
22. Gundlah C., Simon L.D., Auerbach S.B. Differences in hypothalamic serotonin between estrous phases and gender: an in vivo microdialysis study. Brain Res. 1998, 785:91-96.
23. Guptarak J., Selvamani A., Uphouse L. GABAA-5-HT1A receptor interaction in the mediobasal hypothalamus. Brain Res. 2004, 1027:144-150.
24. Hartmann U. Depression and sexual dysfunction: aspects of a multi-faceted relationship. Psychiatr. Prax. 2007, 34(Suppl 3):S314-S317.
25. Hensler J.G. Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci. 2003, 72:1665-1682.
26. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 1994, 9(Suppl 1):19-26.
27. Invernizzi R., Bramante M., Samanin R. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 1996, 54:143-147.
28. Lambert J.J., Belelli D., Peden D.R., Vardy A.W., Peters J.A. Neurosteroid modulation of GABAA receptors. Prog. Neurobiol. 2003, 71:67-80.
29. Lapiz-Bluhm M.D., Bondi C.O., Doyen J., Rodriguez G.A., Bedard-Arana T., Morilak D.A. Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats. J. Neuroendocrinol. 2008, 20:1115-1137.
30. Li Q., Muma N.A., van de Kar L.D. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J. Pharmacol. Exp. Ther. 1996, 279:1035-1042.
31. Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav. Pharmacol. 1997, 8:523-532.
32. Malagie I., Trillat A.C., Jacquot C., Gardier A.M. Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study. Eur. J. Pharmacol. 1995, 286:213-217.
33. Martel J.C., Leduc N., Ormiere A.M., Faucillon V., Danty N., Culie C., Cussac D., Newman-Tancredi A. WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur. J. Pharmacol. 2007, 574:15-19.
34. Maswood N., Caldarola-Pastuszka M., Uphouse L. 5-HT3 receptors in the ventromedial nucleus of the hypothalamus and female sexual behavior. Brain Res. 1997, 769:13-20.
35. Maswood N., Caldarola-Pastuszka M., Uphouse L. Functional integration among 5-hydroxytryptamine receptor families in the control of female rat sexual behavior. Brain Res. 1998, 802:98-103.
36. Maswood S., Truitt W., Hotema M., Caldarola-Pastuszka M., Uphouse L. Estrous cycle modulation of extracellular serotonin in mediobasal hypothalamus: role of the serotonin transporter and terminal autoreceptors. Brain Res. 1999, 831:146-154.
37. Matuszczyk J.V., Larsson K., Eriksson E. Subchronic administration of fluoxetine impairs estrous behavior in intact female rats. Neuropsychopharmacology 1998, 19:492-498.
38. Mendelson S.D. A review and reevaluation of the role of serotonin in the modulation of lordosis behavior in the female rat. Neurosci. Biobehav. Rev. 1992, 16:309-350.
39. Micevych P., Sinchak K. Synthesis and function of hypothalamic neuroprogesterone in reproduction. Endocrinology 2008, 149:2739-2742.
40. Micevych P., Soma K.K., Sinchak K. Neuroprogesterone: key to estrogen positive feedback?. Brain Res. Rev. 2008, 57:470-480.
41. Michelson D., Schmidt M., Lee J., Tepner R. Changes in sexual function during acute and six-month fluoxetine therapy: a prospective assessment. J. Sex Marital Ther. 2001, 27:289-302.
42. Perry K.W., Fuller R.W. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum. Life Sci. 1992, 50:1683-1690.
43. Piazza L.A., Markowitz J.C., Kocsis J.H., Leon A.C., Portera L., Miller N.L., Adler D. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am. J. Psychiatry 1997, 154:1757-1759.
44. Pinna G., Costa E., Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr. Opin. Pharmacol. 2009, 9:24-30.
45. Raap D.K., Evans S., Garcia F., Li Q., Muma N.A., Wolf W.A., Battaglia G., Van De Kar L.D. Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J. Pharmacol. Exp. Ther. 1999, 288:98-106.
46. Raap D.K., DonCarlos L., Garcia F., Muma N.A., Wolf W.A., Battaglia G., Van de Kar L.D. Estrogen desensitizes 5-HT(1A) receptors and reduces levels of G(z), G(i1) and G(i3) proteins in the hypothalamus. Neuropharmacology 2000, 39:1823-1832.
47. Renner K.J., Krey L.C., Luine V.N. Effect of progesterone on monoamine turnover in the brain of the estrogen-primed rat. Brain Res. Bull. 1987, 19:195-202.
48. Rossi A., Barraco A., Donda P. Fluoxetine: a review on evidence based medicine. Ann. Gen. Hosp. Psychiatry 2004, 3:2.
49. Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 2003, 28:139-168.
50. Sanchez C., Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 1999, 19:467-489.
51. Sarkar J., Hiegel C., Ginis G.E., Hilbun E., Uphouse L. Subchronic treatment with fluoxetine attenuates effects of acute fluoxetine on female rat sexual behavior. Brain Res. 2008, 1190:56-64.
52. Segraves R.T. Sexual dysfunction associated with antidepressant therapy. Urol. Clin. North Am. 2007, 34:575-579. vii.
53. Simpson K., Noble S. Fluoxetine: a review of its use in women's health. CNS Drugs 2000, 14:301-328.
54. Snoeren E., Chan J.S.W., Cuppen E., Olivier B., Oosting R.S. 5-HT1A receptor desensitization as mechanism underlying the lack of sexual dysfunction in female serotonin transporter knockout rats. Eur. Neuropsychopharmacol. 2009, 19:S52-S53.
55. Stokes P.E., Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin. Ther. 1997, 19:1135-1250.
56. Sukoff Rizzo S.J., Schechter L.E., Rosenzweig-Lipson S. A novel approach for predicting antidepressant-induced sexual dysfunction in rats. Psychopharmacology (Berl) 2008, 195:459-467.
57. Sukoff Rizzo S.J., Pulicicchio C., Malberg J.E., Andree T.H., Stack G.P., Hughes Z.A., Schechter L.E., Rosenzweig-Lipson S. 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats. Int. J. Neuropsychopharmacol. 2009, 12:1045-1053.
58. Tao R., Fray A., Aspley S., Brammer R., Heal D., Auerbach S. Effects on serotonin in rat hypothalamus of d-fenfluramine, aminorex, phentermine and fluoxetine. Eur. J. Pharmacol. 2002, 445:69-81.
59. Taylor M.J. Strategies for managing antidepressant-induced sexual dysfunction: a review. Curr. Psychiatry Rep. 2006, 8:431-436.
60. Tohyama Y., Yamane F., Merid M.F., Diksic M. Effects of selective 5-HT1A receptor antagonists on regional serotonin synthesis in the rat brain: an autoradiographic study with alpha-[14C]methyl-l-tryptophan. Eur. Neuropsychopharmacol. 2001, 11:193-202.
61. Truitt W., Harrison L., Guptarak J., White S., Hiegel C., Uphouse L. Progesterone attenuates the effect of the 5-HT1A receptor agonist, 8-OH-DPAT, and of mild restraint on lordosis behavior. Brain Res. 2003, 974:202-211.
62. Uphouse L. Female gonadal hormones, serotonin, and sexual receptivity. Brain Res. Brain Res. Rev. 2000, 33:242-257.
63. Uphouse L., Wolf A. WAY100635 and female rat lordosis behavior. Brain Res. 2004, 1013:260-263.
64. Uphouse L., Andrade M., Caldarola-Pastuszka M., Maswood S. Hypothalamic infusion of the 5-HT2/1C agonist, DOI, prevents the inhibitory actions of the 5-HT1A agonist, 8-OH-DPAT, on lordosis behavior. Pharmacol. Biochem. Behav. 1994, 47:467-470.
65. Uphouse L., Andrade M., Caldarola-Pastuszka M., Jackson A. 5-HT1A receptor antagonists and lordosis behavior. Neuropharmacology 1996, 35:489-495.
66. Uphouse L., Hensler J.G., Sarkar J., Grossie B. Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats. Brain Res. 2006, 1072:79-90.
67. Uzunov D.P., Cooper T.B., Costa E., Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:12599-12604.
68. Van de Kar L.D., Raap D.K., Battaglia G., Muma N.A., Garcia F., DonCarlos L.L. Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors. Neuropharmacology 2002, 43:45-54.
69. Vicentic A., Li Q., Battaglia G., Van de Kar L.D. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion. Eur. J. Pharmacol. 1998, 346:261-266.
70. White S., Uphouse L. Estrogen and progesterone dose-dependently reduce disruptive effects of restraint on lordosis behavior. Horm. Behav. 2004, 45:201-208.
71. Wolf A., Caldarola-Pastuszka M., Uphouse L. Facilitation of female rat lordosis behavior by hypothalamic infusion of 5-HT(2A/2C) receptor agonists. Brain Res. 1998, 779:84-95.
72. Wolf A., Caldarola-Pastuszka M., DeLashaw M., Uphouse L. 5-HT2C receptor involvement in female rat lordosis behavior. Brain Res. 1999, 825:146-151.